TP53 and hepatocellular carcinoma: Recent studies have utilized AFP for guiding therapeutic decisions and prognostic analysis and monitoring HCC treatment [43].The results of our meta-analysis showed that AFP levels in patients after rAd-p53 combined with TACE treatment were lower than those in the control group.